Siddhartha S Mitra
Overview
Explore the profile of Siddhartha S Mitra including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
3412
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Iwanaga R, Yamamoto T, Gomez K, Nguyen L, Woodruff E, Post M, et al.
Cancer Res Commun
. 2024 Jul;
4(8):1919-1932.
PMID: 38984891
Significance: CBX2 expression correlates with the TIME. CBX2 modulation shifts the macrophage population, potentially leading to an immunosuppressive microenvironment, highlighting CBX2 as a target to improve efficacy of immunotherapy.
2.
Prince E, Apps J, Jeang J, Chee K, Medlin S, Jackson E, et al.
Neuro Oncol
. 2024 Feb;
26(6):1109-1123.
PMID: 38334125
Background: Cellular senescence can have positive and negative effects on the body, including aiding in damage repair and facilitating tumor growth. Adamantinomatous craniopharyngioma (ACP), the most common pediatric sellar/suprasellar brain...
3.
Lakshmanachetty S, Mitra S
Nat Immunol
. 2022 May;
23(6):826-828.
PMID: 35624212
No abstract available.
4.
Madhavan K, Balakrishnan I, Lakshmanachetty S, Pierce A, Sanford B, Fosmire S, et al.
Clin Cancer Res
. 2022 Mar;
28(11):2409-2424.
PMID: 35344040
Purpose: Tumor relapse after radiotherapy is a major hurdle in treating pediatric H3K27M-mutant diffuse midline gliomas (DMG). Radiotherapy-induced stress increases association of BCL2 family of proteins with BH3 pro-apoptotic activators...
5.
Lakshmanachetty S, Cruz-Cruz J, Hoffmeyer E, Cole A, Mitra S
Cells
. 2021 Apr;
10(4).
PMID: 33919732
Cancer cells "hijack" host immune cells to promote growth, survival, and metastasis. The immune microenvironment of high-grade gliomas (HGG) is a complex and heterogeneous system, consisting of diverse cell types...
6.
Lentz R, Colton M, Mitra S, Messersmith W
Mol Cancer Ther
. 2021 Apr;
20(6):961-974.
PMID: 33850005
While immunotherapy has revolutionized the treatment of many types of advanced cancer, most patients still do not derive benefit. The currently available immune checkpoint inhibitors target the adaptive immune system,...
7.
Cole A, Hoffmeyer E, Chetty S, Cruz-Cruz J, Hamrick F, Youssef O, et al.
Adv Exp Med Biol
. 2020 Oct;
1273:197-208.
PMID: 33119883
Microglia are the brain resident phagocytes that act as the primary form of the immune defense in the central nervous system. These cells originate from primitive macrophages that arise from...
8.
Theruvath J, Sotillo E, Mount C, Graef C, Delaidelli A, Heitzeneder S, et al.
Nat Med
. 2020 Apr;
26(5):712-719.
PMID: 32341579
Atypical teratoid/rhabdoid tumors (ATRTs) typically arise in the central nervous system (CNS) of children under 3 years of age. Despite intensive multimodal therapy (surgery, chemotherapy and, if age permits, radiotherapy),...
9.
Danilov A, Herbaux C, Walter H, Hillmen P, Rule S, Kio E, et al.
Clin Cancer Res
. 2020 Mar;
26(12):2810-2818.
PMID: 32156743
Purpose: Bruton tyrosine kinase (BTK) inhibition alone leads to incomplete responses in chronic lymphocytic leukemia (CLL). Combination therapy may reduce activation of escape pathways and deepen responses. This open-label, phase...
10.
Majzner R, Theruvath J, Nellan A, Heitzeneder S, Cui Y, Mount C, et al.
Clin Cancer Res
. 2019 Jan;
25(8):2560-2574.
PMID: 30655315
Purpose: Patients with relapsed pediatric solid tumors and CNS malignancies have few therapeutic options and frequently die of their disease. Chimeric antigen receptor (CAR) T cells have shown tremendous success...